Literature DB >> 11375114

AP-1--glucocorticoid receptor crosstalk taken to a higher level.

M Karin1, L Chang.   

Abstract

More than a decade ago our view of gene regulation by glucocorticoids (GC) and other steroid hormones underwent a dramatic change with the discovery of negative crosstalk (transcriptional interference) between the GC receptor (GCR) and transcription factor AP-1 (Jun:Fos). It was initially observed that induction of the collagenase type 1 gene, which is mediated through activation of AP-1 by growth factors and inflammatory cytokines, is repressed by GC. This repression was attributed to mutual negative interactions between AP-1 and GCR. Although the exact molecular mechanism underlying this particular case of transcriptional interference is yet to be determined, it has become clear that this and analogous interactions with other transcription factors (e.g. nuclear factor-kappaB) underlie the anti-inflammatory and immunosuppressive activity of GC. Recent studies conducted at the whole animal level indicate that the interactions between the AP-1 and GC signaling pathways are much more extensive. AP-1-related signaling via the Jun N-terminal kinases can lead to increased levels of circulating GC, which eventually down-modulate AP-1 activity via transcriptional interference. This negative feedback loop is likely to be of great importance for maintenance of homeostasis and regulation of stress responses, including acute and chronic inflammation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11375114     DOI: 10.1677/joe.0.1690447

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  34 in total

Review 1.  New and emerging pharmacological targets for neuropathic pain.

Authors:  Donald C Manning
Journal:  Curr Pain Headache Rep       Date:  2004-06

Review 2.  Psychological stress and aging: role of glucocorticoids (GCs).

Authors:  K M Mehedi Hasan; Md Shaifur Rahman; K M T Arif; Mahbub E Sobhani
Journal:  Age (Dordr)       Date:  2011-10-05

3.  Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor.

Authors:  Chunyu Wang; Julie Ann Mayer; Abhijit Mazumdar; Kirsten Fertuck; Heetae Kim; Myles Brown; Powel H Brown
Journal:  Mol Endocrinol       Date:  2011-08-11

4.  STAMP, a novel predicted factor assisting TIF2 actions in glucocorticoid receptor-mediated induction and repression.

Authors:  Yuanzheng He; S Stoney Simons
Journal:  Mol Cell Biol       Date:  2006-11-20       Impact factor: 4.272

5.  A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters.

Authors:  Olivier Kassel; Sandra Schneider; Christine Heilbock; Margarethe Litfin; Martin Göttlicher; Peter Herrlich
Journal:  Genes Dev       Date:  2004-10-15       Impact factor: 11.361

6.  Glucocorticoid and growth factor synergism requirement for Notch4 chromatin domain activation.

Authors:  Jing Wu; Emery H Bresnick
Journal:  Mol Cell Biol       Date:  2007-01-12       Impact factor: 4.272

Review 7.  Glucocorticoid receptor: implications for rheumatic diseases.

Authors:  T Kino; E Charmandari; G P Chrousos
Journal:  Clin Exp Rheumatol       Date:  2011-10-21       Impact factor: 4.473

8.  Transcriptional activity of c-Jun is critical for the suppression of AR function.

Authors:  Chih-Chao Hsu; Chang-Deng Hu
Journal:  Mol Cell Endocrinol       Date:  2013-03-21       Impact factor: 4.102

9.  The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation, and transformation.

Authors:  Susana García-Silva; Ana Aranda
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

10.  Anthrax lethal factor represses glucocorticoid and progesterone receptor activity.

Authors:  Jeanette I Webster; Leonardo H Tonelli; Mahtab Moayeri; S Stoney Simons; Stephen H Leppla; Esther M Sternberg
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-30       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.